欢迎访问行业研究报告数据库

行业分类

当前位置:首页 > 报告详细信息

找到报告 1 篇 当前为第 1 页 共 1

专门针对卵巢癌的纳米二氧化铈与叶酸共轭的临床前评价

Preclinical Evaluation to Specifically Target Ovarian Cancer with Folic Acid conjugated Nanoceria

作者:Rattan, R.; Seal, S. 作者单位:Henry Ford Health System, Detroit, MI. 加工时间:2015-03-16 信息来源:科技报告(AD) 索取原文[18 页]
关键词:叶酸;卵巢癌;抗氧化剂;细胞(生物学);临床医学;增长(生理学);体外分析;体内分析;标记物质;肿瘤;卵巢;效力;感觉器官,测试和评估;毒性
摘 要:Despite the fact that there have been significant developments in anti-cancer technology, ovarian cancer still remains one of the leading causes of gynecological cancer deaths in the United States. To contribute towards novel approaches with minimal toxicity in treatment of ovarian cancer we proposed the present work, where we are integrating the field of nanotechnology with ovarian cancer cells unique property of overexpressing folic acid receptor alpha (FR- ) to specifically target ovarian cancer. A cerium oxide nanoparticle, called Nanoceria (NCe), that has the ability to act as an anti- oxidant in similar capacity as biological anti-oxidants was selected. NCe in our hands exhibited efficacy in inhibiting ovarian tumor growth in vivo. Taking advantage of the nanotechnology, NCe was conjugated with molecules of folic acid to specifically target ovarian tumors as they are known to over-express folate receptor. This would result in specific killing of ovarian cells by NCe while minimizing toxicity to normal tissue. Dr Seal s laboratory (UCF) was able to successfully conjugate NCe to folic acid to prepare folic acid tagged Nanoceria called FA-NCe. FA-NCe was tested in vitro and was observed to have higher anti-growth activity against ovarian cancer cells. When given in animals, FA-NCe was more potent in inhibiting ovarian tumor growth than NCe alone.
© 2016 武汉世讯达文化传播有限责任公司 版权所有 技术支持:武汉中网维优
客服中心

QQ咨询


点击这里给我发消息 客服员


电话咨询


027-87841330


微信公众号




展开客服